hepg2 red fluc cell line Search Results


hepg2 red fluc cell line  (Revvity)
92
Revvity hepg2 red fluc cell line
Half-maximal inhibitory concentration (IC 50 ) of apatinib and sorafenib in hepatocellular carcinoma cell lines
Hepg2 Red Fluc Cell Line, supplied by Revvity, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hepg2 red fluc cell line/product/Revvity
Average 92 stars, based on 1 article reviews
hepg2 red fluc cell line - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

Image Search Results


Half-maximal inhibitory concentration (IC 50 ) of apatinib and sorafenib in hepatocellular carcinoma cell lines

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: Half-maximal inhibitory concentration (IC 50 ) of apatinib and sorafenib in hepatocellular carcinoma cell lines

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Concentration Assay

a HepG2-Red-fLuc and ( b ) SMMC-7721-fLuc cell-derived tumor-bearing mice on days 0, 6, 12, and 18 post-drug treatment. Changes in BLI signal intensity, tumor volume, and mouse body weight in mice bearing HepG2-Red-fLuc ( c, e, g ) and SMMC-7721-fLuc ( d, f, h ) cell xenograft tumors were evaluated. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 vs. the control group

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: a HepG2-Red-fLuc and ( b ) SMMC-7721-fLuc cell-derived tumor-bearing mice on days 0, 6, 12, and 18 post-drug treatment. Changes in BLI signal intensity, tumor volume, and mouse body weight in mice bearing HepG2-Red-fLuc ( c, e, g ) and SMMC-7721-fLuc ( d, f, h ) cell xenograft tumors were evaluated. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 vs. the control group

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Derivative Assay, Control

a BLI signals of orthotopic HepG2-Red-fLuc cell-derived tumor-bearing mice on days 0, 3, 6, 9, 12, 15, and 18 post-drug treatment. b BLI signal intensity of mice. (*) P < 0.05, (**) P < 0.01 vs. the control group. c Body weight of mice. (*) P < 0.05, day 6 vs. day 0 in the sorafenib group. d The 3D BLT reconstruction in the control and sorafenib and apatinib treatment groups on day 20 post-drug treatment

Journal: Experimental & Molecular Medicine

Article Title: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

doi: 10.1038/s12276-019-0274-7

Figure Lengend Snippet: a BLI signals of orthotopic HepG2-Red-fLuc cell-derived tumor-bearing mice on days 0, 3, 6, 9, 12, 15, and 18 post-drug treatment. b BLI signal intensity of mice. (*) P < 0.05, (**) P < 0.01 vs. the control group. c Body weight of mice. (*) P < 0.05, day 6 vs. day 0 in the sorafenib group. d The 3D BLT reconstruction in the control and sorafenib and apatinib treatment groups on day 20 post-drug treatment

Article Snippet: The HepG2-Red-fLuc cell line was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Derivative Assay, Control